{"id":"tofacitinib-10mg","safety":{"commonSideEffects":[{"effect":"Abnormal liver function","drugRate":"15.0%","placeboRate":"","totalAtRisk":20,"totalAffected":3,"trialsReporting":1}]},"_chembl":null,"_fixedAt":"2026-03-30T11:37:34.027019","allNames":"tofacitinib 10mg","_dailymed":null,"mechanism":{"target":"JAK","drugClass":"JAK inhibitor","explanation":"Tofacitinib blocks the activity of Janus kinases (JAKs), which are enzymes involved in the signaling pathways of various cytokines. By inhibiting JAKs, tofacitinib reduces the inflammatory response in conditions like rheumatoid arthritis.","oneSentence":"Tofacitinib inhibits Janus kinases (JAKs), reducing cytokine signaling and inflammation."},"_scrapedAt":"2026-03-28T00:43:53.121Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:38:05.844619+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_fixedFields":["pubmed(4)"],"trialDetails":[],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"recentPublications":[{"date":"2022 Oct","pmid":"36210142","title":"Takotsubo Syndrome in a Rheumatoid Arthritis Patient Under Tofacitinib: A Case Report.","journal":"Reumatologia clinica"},{"date":"2021","pmid":"34156015","title":"EFFECT OF PROLONGED TREATMENT WITH BIOLOGICAL THERAPY IN PATIENTS WITH ULCERATIVE COLITIS WITH CONCOMITENT JOINT DAMAGE.","journal":"Wiadomosci lekarskie (Warsaw, Poland : 1960)"},{"date":"2017 Oct","pmid":"28558978","title":"The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study.","journal":"Journal of dermatological science"},{"date":"2016 May 1","pmid":"27168266","title":"Efficacy of Tofacitinib for the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis in Patient Subgroups from Two Randomised Phase 3 Trials.","journal":"Journal of drugs in dermatology : JDD"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Tofacitinib 10mg","genericName":"tofacitinib-10mg","companyName":"Pfizer Inc.","companyId":"pfizer","modality":"","firstApprovalDate":"","aiSummary":"Tofacitinib 10mg is a small molecule Janus Kinase (JAK) inhibitor. It has been studied in clinical trials for various conditions, including COVID-19 pneumonia, interstitial pneumonitis, and alopecia areata.","enrichmentLevel":5,"visitCount":4,"trialStats":{"total":8,"withResults":1},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:38:05.844619+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":true,"trials":false,"score":2}}